Is prophylactic tranexamic acid administration effective and safe for postpartum hemorrhage prevention?  
A systematic review and meta-analysis

Chunbo Li, MD	extsuperscript{a}, Yuying Gong	extsuperscript{b}, Lingling Dong, MD	extsuperscript{a}, Bingying Xie, MD	extsuperscript{c}, Zhiyuan Dai, MD	extsuperscript{a,∗}

Abstract
Background: To assess the efficacy and safety of tranexamic acid (TA) in reducing blood loss and lowering transfusion needs for patients undergoing caesarean section (CS) or vaginal delivery (VD).

Methods: An electronic literature search of PubMed, EMBASE, OVID, Cochrane library, Scopus, Central, and Clinical trials.gov was performed to identify studies that evaluating the usage of TA in CS or VD. The methodological quality of included trials was assessed and data extraction was performed.

Results: Finally, 25 articles with 4747 participants were included. Our findings indicated TA resulted in a reduced intra-, postoperative, and total blood loss by a mean volume of 141.25 mL (95% confidence interval [CI] = 186.72 to −95.79, \( P < 0.00001 \)), 36.42 mL (95% CI = −46.50 to −26.34, \( P < 0.00001 \)), and 154.25 mL (95% CI = −182.04 to −126.47, \( P < 0.00001 \)) in CS. TA administration in VD was associated with a reduced intra-, postoperative, and total blood loss by a mean volume of 22.88 mL (95% CI = −50.54 to 4.77, \( P = 0.10 \)), 41.24 mL (95% CI = −55.50 to −26.98, \( P < 0.00001 \)), and 84.79 mL (95% CI = −109.93 to −59.65, \( P < 0.00001 \)). In addition, TA could lower the occurrence rate of postpartum hemorrhage (PPH) and severe PPH, and reduce the risk of blood transfusions. No increased risk of deep vein thrombosis (DVT) after CS or VD was associated with TA usage, while the minor side effects were more common.

Conclusions: Our findings indicated that intravenous TA for patients undergoing CS was effective and safe. Although prophylactic TA administration is associated with reduced PPH, current existing data are insufficient to draw definitive recommendations about its clinical significance due to the poor to moderate quality of the included literatures. Thus, high-quality randomized controlled trials with larger samples are needed to validate our findings.

Abbreviations: CI = confidence interval, CS = caesarean section, DVT = deep vein thrombosis, PPH = postpartum hemorrhage, RCT = randomized controlled trial, TA = tranexamic acid, VD = vaginal delivery.

Keywords: caesarean section, meta-analysis, postpartum hemorrhage, tranexamic acid, vaginal delivery

1. Introduction
Postpartum hemorrhage (PPH) is a potential life-threatening complication of both vaginal (VD) or cesarean delivery.\textsuperscript{[1]} It is reported that PPH accounts for nearly 25% of maternal deaths and approximately 12% survivors after PPH suffer from severe postpartum anemia.\textsuperscript{[1]} Recently, the occurrence rate of caesarean section (CS) has increased in both developed and developing countries, which would result in an increased risk of PPH.\textsuperscript{[2]} Although there has been a remarkable improvement in the prevention and treatment of PPH in recent years, deaths due to PPH remain relatively common in some parts of the world. To lower the occurrence rate of major morbidity and mortality due to PPH, it is very vital to reduce blood loss in CS and VD. Tranexamic acid (TA), an antifibrinolytic agent, could exert its hemostasis effect via inhibiting the activation of plasminogen to plasmin.\textsuperscript{[3]} Its efficacy and safety in reducing hemorrhage and lowering transfusion requirements have been well established in various elective surgeries.\textsuperscript{[4–6]} Recently, TA has been reported to reduce blood loss in gynecology diseases such as menorrhagia, hysterectomy, and myomectomy.\textsuperscript{[7–9]} Naoulou et al\textsuperscript{[7]} reviewed all available evidence about the use of TA in menorrhagia and concluded that TA was effective and safe and could potentially improve quality of life of patients with heavy menstrual bleeding. Topsoe et al\textsuperscript{[8]} performed a randomized controlled trial (RCT) and revealed that TA could reduce the total blood loss, the incidence of substantial blood loss, and the need for reoperations for patients who underwent benign hysterectomy. Shaaban et al\textsuperscript{[9]} reported that TA reduced blood loss by a mean volume of 407 mL during and after myomectomy for patients with multiple uterine fibroids. Moreover, several studies evaluated the usage of
TA administration in CS\textsuperscript{[10–31]} or VD\textsuperscript{[32–34]} and showed satisfactory outcomes. Although published meta-analyses demonstrated that TA administration in CS or VD could result in a significant reduction in estimated blood loss, most of these studies limited the smaller samples and the poor quality of the included trials.\textsuperscript{[35–38]} Moreover, data about clinical relevance of the reduced blood loss with TA intervention remained inadequate because these outcomes did not distinguish the efficacy of TA administration based on the mode of delivery.

Traditional, PPH is commonly defined as blood loss of more than 500 mL following a VD, or more than 1000 mL following a CS.\textsuperscript{[39]} For a normal woman undergoing CS, a blood loss of 1000 mL seems to be common and had a minimal effect on women’s health status. However, for a woman with severe anemia or cardiovascular disease undergoing VD, a blood loss of as little as 200 mL may be life-threatening and need additional intervention.\textsuperscript{[39,40]} Thus, it is important to evaluate the efficacy and safety of TA on blood loss based on the mode of delivery. As we are aware of at least 8 additional trials\textsuperscript{[23–27,31–33]} for CS and 1 trial\textsuperscript{[34]} for VD published in recent 3 years, which are not included in any published meta-analyses. Thus, we aimed to identify all available data to evaluate whether the mode of delivery had a potential effect on the efficacy of TA in reducing estimated blood loss.

2. Materials and methods

2.1. Search strategy

The relevant literatures involving in intravenous TA for CS or VD were searched using the electronic databases such as Medline, PubMed, EMBASE, OVID, Cochrane library, Scopus, Central, Clinicaltrials.gov, and other databases such as Google scholar, Biomed central, CINHAL, and Chinese databases such as Wanfang, CNKI, and VIP databases. No restrictions for language or geographic location were applied. The combination of terms as medical subject headings (Mesh) for the database searchers were: (Tranexamic acid OR TA OR TXA OR AMCA OR Cyclokapron) AND (pregnancy OR gestation). The last search was updated in June 1, 2016. Reference lists of the included studies and other relevant publications, including case reports, reviews, and meta-analyses, were checked for any unidentified trials from the electronic searches. Abstracts from relevant conferences or scientific meetings were hand-searched for additional studies. Due to the characteristic of meta-analysis, no ethics approval and patient consent was necessary for the study.

2.2. Inclusion criteria

The included studies must meet the following criteria: randomized trials in any language; participants with singleton pregnancy who underwent elective CS or intended to delivery vaginally; all published studies comparing intravenous usage of TA in treatment group and normal saline or 5% glucose in control group; and the evaluation of outcomes by estimated blood loss, transfusion requirements, and complications such as the occurrence rate of deep vein thrombosis (DVT), nausea, vomiting, headache, and dizziness. We excluded the articles according to the following criteria: review articles, case reports, conference proceedings, or repeated publications; no available data reported.

2.3. Study selection and data extraction

The potential studies meeting the included criteria were identified based on the title and abstract information. If there was a doubt existing, the full text would be reviewed for clarification. Then, data were extracted from each study using a standardized form. Demographic data including publication date, sample size, age, gestational age, interventions, and surgery time for each study were recorded. The outcomes of interest including estimated blood loss, the occurrence rate of PPH/severe PPH, transfusion requirements, and drug-induced complications were analyzed. The study selection and data extraction were performed by 2 authors independently (CBL and YPG). Any disagreement for study section between 2 authors was discussed with a senior and if all authors considered that a study did not meet the inclusion criteria, the study was excluded. In case of insufficient data, we would contact the authors of the trials for more information.

2.4. Quality assessment

The methodological quality of each trial was evaluated according to the recommended criteria of CochraneHandbook for systematic Reviews of interventions by 2 independent authors (CBL and YPG). Any differences of opinion regarding methodological quality of included trials were resolved by discussion with a senior author (ZYD).

2.5. Statistical analysis

All statistical analyses were performed according to the guidelines of the Cochrane Collaboration using Review Manager software (RevMan, version 5.2). For dichotomous data including rate of PPH and severe PPH, transfusion needs, and adverse events, the summary ratio risk (RR) with 95% confidence interval (CI) was calculated. For continuous data including total, intra-, and postoperative blood loss, the mean difference with 95% CI was calculated. P < 0.05 was thought to be significant difference. Because of expected substantial heterogeneity, the synthesis of the outcomes for all studies was calculated as the weighted average rate by using a random effect model. Sensitivity analysis was performed to assess the strength and robustness of the pooled results by excluding low quality studies and repeating the analysis for outcomes of interest. When the number of studies allowed, publication bias was evaluated using Funnel plots.

3. Results

3.1. Study inclusion and characteristics

A total of 5647 studies were originally identified using the electronic search system. Subsequently, 5213 studies were readily excluded due to duplication, irrelevancy, or nonrandomized trials after screening the title or abstract and 434 studies remained for further evaluation. After the full-text was obtained and reviewed thoroughly, an additional 405 studies failing to meet the included criteria were excluded. Because no adequate data were obtained, 1 trial by Sharma et al\textsuperscript{[41]} was excluded. One study by Sahhaf et al\textsuperscript{[42]} comparing the antihemorrhagic effect of TA and Misoprostol for PPH and 2 studies by Shakur et al\textsuperscript{[43]} and Ducloy-Bouthors et al\textsuperscript{[44]} evaluating the therapeutic efficacy of TA in postpartum patients were excluded. Finally, a total of 25 randomized trials (22 trials\textsuperscript{[10–31]} for CS and 3 trials\textsuperscript{[32–34]} for VD) were included. The detailed study selection process was presented in Fig. 1.

A total of 25 articles\textsuperscript{[10–34]} included a total of 4747 participants undergoing CS or VD, and no significant differences in preoperative baseline parameters were observed between TA
and control group within each study. All studies reported that TA was administered intravenously using either a weighted or standard dose. For control group, a placebo (normal saline or 5% glucose) was given in all studies. The outcomes of interest including reduced blood loss, transfusion needs, the occurrence rate of PPH and severe PPH, and complications were recorded. The detailed characteristics of the included studies for CS and VD were presented in Table 1, respectively.

The majority of the included trials were small with sample sizes ranging from 60 to 740 patients. However, they were well designed and well implemented. Eighteen trials\[^{10-12,14,15,17-19,21-24,28-31,33,34}\] provided detailed randomization techniques using a computer-generated randomization list, consecutively numbered sealed opaque envelopes or rand list software, while 7 trials\[^{16,20,25-27,31,32}\] referred to randomization only without describing the detailed method. Eleven trials\[^{10,11,13,16,21,25,31,32}\] had unclear bias in the allocation concealment while only 1 study\[^{12}\] presented a higher bias. For the blinding of participants and personnel, there was a higher bias in 7 studies\[^{10,11,13,17,20,23,32}\] due to a lack of information and 6 studies\[^{13,21,25-27,31}\] had an unclear bias in the blinding measurement. Two studies\[^{19,20}\] had an unclear bias due to incomplete outcome data reported, and no studies had selective outcome reporting. In addition, no other sources of bias were detected in any studies. The methodological quality for each study was summarized in Fig. 2.

### 3.2. Blood loss

There were 15 trials\[^{10,11,13,14,16,17,20-23,26-29,31}\] for CS and 3 trials\[^{32-34}\] for VD identified to evaluate the effect of TA on total reduced blood loss (from fetus delivery to 2 hours postpartum). Our results indicated TA administration in CS resulted in a reduced blood loss by a mean volume of 154.25 mL (95% CI = 109.93 to 198.57; \(I^2 = 98\%\)) and a reduced blood loss by a mean volume of 84.79 mL (95% CI = 59.65 to 110.93; \(I^2 = 0\%\)) in VD as compared to control group. The test for subgroup differences showed a significant difference (\(P = 0.0003\)), indicating the efficacy of TA administration in reducing total blood loss was affected by the mode of delivery (Fig. 3A).

A total of 614 trials\[^{10,11,13,17,19,22-25,27,28,31}\] and 2 trials\[^{32,34}\] provided detailed data on the effect of TA on the intraoperative blood loss (from fetus delivery to placental delivery) in CS and VD, respectively. Our results indicated that TA administration in CS resulted in a reduced blood loss by a mean volume of 141.25 mL (95% CI = 186.72 to 95.79; \(I^2 = 99\%\)) and a reduced blood loss by a mean volume of 22.88 mL (95% CI = 47.77 to 50.54; \(I^2 = 0\%\)) in VD as compared to control group. However, the latter did not reach a statistical difference. The test for subgroup differences showed significantly difference (\(P < 0.0001\)), indicating the efficacy of TA administration in reducing intraoperative blood loss was affected by the mode of delivery (Fig. 3B).

Data on the postoperative blood loss (from placental delivery to 2 hours postpartum) was available in 14 trials\[^{10-13,15,17,18,22-25,27,28,31}\] for CS and 2 trials\[^{32,34}\] for VD. Our results showed TA administration in CS resulted in a reduced blood loss by a mean volume of 36.42 mL (95% CI = 46.50 to 26.34; \(I^2 = 98\%\)) and a reduced blood loss by a mean volume of 41.24 mL (95% CI = 55.50 to 26.98; \(I^2 = 0\%\)) in VD as compared to control. However, the test for subgroup differences showed no significantly difference (\(P = 0.59\)), indicating the mode of delivery had no significant effect on the efficacy of TA administration in reducing postoperative blood loss (Fig. 3C).

### 3.3. Rate of PPH or severe PPH

The outcome measure of PPH was available in 8 trials\[^{10,11,13,17,18,22-25,28,29}\] in CS and 3 trials\[^{32-34}\] in VD (Fig. 4A). Our results showed that TA administration lowered...
### Table 1
Characteristics of included trials.

| Study, year       | Country  | TA/control (n) | Age, year | Gestational age, year | Intervention                                                                 | Transfusion standardized | Adverse effects |
|-------------------|----------|----------------|-----------|-----------------------|-------------------------------------------------------------------------------|--------------------------|-----------------|
| Cesarean section  |          |                |           |                       |                                                                                |                          |                 |
| Gai (2004)        | China    | 91/89          | TA: 29.7±4.18 CON: 29.75±4.01 | TA: 38.8±1.11 CON: 38.67±1.03 | TA: 1 g TA IV over 10 minutes before CS. CON: 5% glucose | NR                        | DVT             |
| Mayur (2007)      | India    | 50/50          | TA: 24.3±3.65 CON: 24.89±3.99 | TA: 38.5±1.29 CON: 38.64±1.24 | TA: 1 g TA IV over 20 minutes before CS CON: normal saline | NR                        | DVT             |
| Selehart (2009)   | Iran     | 45/45          | TA: 26.2±4.7 CON: 27.1±4.1 | TA: 38.8±0.6 CON: 38.7±0.6 | TA: 1 g TA IV over 10 minutes before CS CON: 5% glucose | NR                        | DVT             |
| Rashmi (2010)     | India    | 50/50          | TA: 25.7±3.7 CON: 25.10±4.73 | TA: 37.85±1.09 CON: 37.90±0.96 | TA: 1 g TA IV 30 minutes before CS CON: normal saline | NR                        | DVT             |
| Gungorduk (2011)  | Turkey   | 330/330        | TA: 26.3±3.5 CON: 26.6±3.6 | TA: 38.8±0.6 CON: 38.7±0.6 | TA: 1 g TA IV 10 minutes before CS CON: 5% glucose | NR                        | An estimated blood loss >1000 mL | DVT             |
| Movafegh (2011)   | India    | 50/50          | TA: 25.7±3.7 CON: 25.10±4.73 | TA: 38.8±0.6 CON: 38.7±0.6 | TA: 1 g TA IV 10 minutes before CS CON: normal saline | NR                        | NR DVT nausea, vomiting |
| Sekhavat (2009)   | Iran     | 45/45          | TA: 26.2±4.7 CON: 27.1±4.1 | TA: 38.8±0.6 CON: 38.7±0.6 | TA: 1 g TA IV 10 minutes before CS CON: normal saline | NR                        | NR DVT nausea, vomiting |
| Rashmi (2010)     | India    | 50/50          | TA: 25.7±3.7 CON: 25.10±4.73 | TA: 37.85±1.09 CON: 37.90±0.96 | TA: 1 g TA IV 30 minutes before CS CON: normal saline | NR                        | NR DVT nausea, vomiting |
| Mayur (2007)      | India    | 50/50          | TA: 24.3±3.65 CON: 24.89±3.99 | TA: 38.5±1.29 CON: 38.64±1.24 | TA: 1 g TA IV over 20 minutes before CS CON: normal saline | NR                        | NR DVT nausea, vomiting |
| Sekhavat (2009)   | Iran     | 45/45          | TA: 26.2±4.7 CON: 27.1±4.1 | TA: 38.8±0.6 CON: 38.7±0.6 | TA: 1 g TA IV 10 minutes before CS CON: normal saline | NR                        | NR DVT nausea, vomiting |
| Rashmi (2010)     | India    | 50/50          | TA: 25.7±3.7 CON: 25.10±4.73 | TA: 37.85±1.09 CON: 37.90±0.96 | TA: 1 g TA IV 30 minutes before CS CON: normal saline | NR                        | NR DVT nausea, vomiting |
| Gungorduk (2011)  | Turkey   | 330/330        | TA: 26.3±3.5 CON: 26.6±3.6 | TA: 38.8±0.6 CON: 38.7±0.6 | TA: 1 g TA IV 10 minutes before CS CON: normal saline | NR                        | NR DVT nausea, vomiting |
| Movafegh (2011)   | India    | 50/50          | TA: 25.7±3.7 CON: 25.10±4.73 | TA: 38.8±0.6 CON: 38.7±0.6 | TA: 1 g TA IV 10 minutes before CS CON: normal saline | NR                        | NR DVT nausea, vomiting |
| Shahid (2013)     | Pakistan | 38/36          | TA: 26.2±4.7 CON: 27.1±4.1 | TA: 38.8±0.6 CON: 38.7±0.6 | TA: 1 g TA IV 10 minutes before CS CON: normal saline | NR                        | NR DVT nausea, vomiting |
| Goswami (2013)    | India    | 50/50          | TA: 23.6±2.5 CON: 24.3±2.6 | TA: 39.3±1.1 CON: 39.3±1.17 | TA: 1 g TA IV 10 minutes before CS CON: none | NR                        | NR DVT nausea, vomiting |
| Abdel-Aleem (2013)| Switzerland | 373/367 | TA: 26.3±4.15 CON: 26.6±4.55 | TA: 39.3±1.24 CON: 39.3±1.28 | TA: 1 g TA IV over 10 minutes before CS CON: none | NR                        | NR DVT nausea, vomiting |
| Halder (2013)     | India    | 50/50          | TA: 26.0±2.51 CON: 26.0±2.51 | TA: 39±2 CON: 39±2 | TA: 1 g TA IV 10 minutes before CS CON: none | NR                        | NR DVT nausea, vomiting |
| Taj (2014)        | Pakistan | 60/60          | TA: 23.6±3.62 CON: 24.18±3.47 | TA: 39.1±1.1 CON: 39.0±1.2 | TA: 1 g TA IV 20 minutes before CS CON: normal saline | NR                        | NR DVT nausea, vomiting |
| Singh (2014)      | India    | 100/100        | TA: 25±1.46 CON: 26±2 | TA: 39.1±1.24 CON: 39.3±1.28 | TA: 1 g TA IV 10 minutes before CS. CON: 5% glucose | NR                        | NR DVT nausea, vomiting |
| Ahmed (2014)      | Egypt    | 62/62          | TA: 28.6±5.9 CON: 26.9±3.7 | TA: 38.5±0.7 CON: 38.5±0.7 | TA: 10mg/kg TA IV 10-20 minutes before CS CON: normal saline | NR                        | NR DVT nausea, vomiting |
| Yehia (2014)      | Egypt    | 106/106        | TA: 28.4±4.9 CON: 28.6±4.7 | TA: 39.1±1.1 CON: 39.0±1.2 | TA: 1 g TA IV over 20 minutes before CS CON: normal saline | NR                        | NR DVT nausea, vomiting |
| Gobbur (2014)     | India    | 50/50          | TA: 23.6±3.429 CON: 24.5±3.982 | TA: 38.6±0.779 CON: 38.72±0.671 | TA: 1 g TA IV 10 minutes before CS CON: normal saline | NR                        | NR DVT nausea, vomiting |
| Ramani (2014)     | India    | 60/60          | TA: 24.9±3.9 CON: 24.4±3.7 | TA: 38.6±0.779 CON: 38.72±0.671 | TA: 1 g TA IV 20 minutes before CS CON: normal saline | NR                        | NR DVT nausea, vomiting |
| Maged (2015)      | Egypt    | 70/70          | TA: 25.9±3.7 CON: 26.0±3.1 | TA: 38.6±0.779 CON: 38.72±0.671 | TA: 1 g TA IV 20 minutes before CS CON: normal saline | NR                        | NR DVT nausea, vomiting |
| Sujata (2016)     | India    | 31/29          | TA: 29.4±4.16 CON: 30.27±4.31 | TA: 39.1±1.24 CON: 39.3±1.28 | TA: 1 g TA IV 15 minutes before CS CON: normal saline | NR                        | NR DVT nausea, vomiting |
the occurrence rate of PPH as compared to control group in CS (RR 0.32, 95% CI 0.16–0.61, $I^2=91\%$) and VD (RR 0.37, 95% CI 0.20–0.67, $I^2=28\%$). However, the test for subgroup differences showed no significant difference ($P=0.75$), indicating the mode of delivery had no significant effect on the efficacy of TA administration in occurrence rate of PPH.

The outcome measure of severe PPH was available in 4 trials\textsuperscript{14,17,29,30} in CS and 2 trials\textsuperscript{33,34} for VD (Fig. 4B). Our results showed that TA administration in CS lowered significantly the occurrence rate of severe PPH as compared to control group (RR 0.32, 95% CI 0.12–0.84, $I^2=19\%$). For VD, no significant difference on the occurrence rate of severe PPH was found between TA and control group (RR 0.30, 95% CI 0.06–1.47, $I^2=0\%$). However, the test for subgroup differences showed no significant difference ($P=0.95$), indicating the mode of delivery had no significant effect on the efficacy of TA administration in occurrence rate of severe PPH.

### 3.4. Transfusion needs

The outcome measure of transfusion needs was available in 8 trials\textsuperscript{14,18,19,22,24,28,30,31} in CS and 1 trial\textsuperscript{33} in VD (Fig. 4C). Our results showed that TA administration lowered the transfusion needs as compared to control in CS (RR 0.31, 95% CI 0.18–0.51, $I^2=0\%$) but not in VD (RR 0.33, 95% CI 0.03–3.17, $I^2=0\%$). The test for subgroup differences showed no significantly difference ($P=0.95$), indicating the mode of delivery had no significant effect on the efficacy of TA administration in transfusion needs.

### 3.5. Adverse events

All component studies provided data on thromboembolic complication in CS and VD (Fig. 5A). However, only 4 trials\textsuperscript{18,19,21,22} involving in women undergoing CS reported 4 DVT in TA group and 6 DVT in control group. The pooled results showed that TA administration had no significant difference (RR 0.60, 95% CI 0.20–1.85, $I^2=0\%$) between TA group and control group. Besides thromboembolic episodes, some other minor adverse events including nausea, vomiting, headache, and dizziness were compared between TA group and control group (Fig. 5B). Our results showed that TA administration resulted in increased risk of minor transient adverse events as compared to control group in CS (RR 1.74, 95% CI 1.13–2.68, $I^2=0\%$) or VD (RR 2.11, 95% CI 1.55–2.88, $I^2=0\%$).

### 3.6. Publication bias and sensitivity analysis

Thromboembolic complication was used to generate funnel plot analysis of publication bias (Fig. 6). The plot presented no clear asymmetrical, and all studies fell within the 95% CI axis, which indicated no existence of significant publication bias existing. Sensitivity analysis was conducted by repeating the analysis after excluding 4 studies\textsuperscript{13,25,31,32} with high risk of bias, the results remained unchanged.

### 4. Discussion

Our meta-analysis demonstrated that intravenous TA administration for patients undergoing CS could effectively reduce blood loss and transfusion needs, as well as lower the occurrence rate of PPH and severe PPH with only minor side effects, yet do not result in an increased risk of postoperative DVT. However, the
conclusion should be interpreted cautiously to assess the efficacy of TA for patients undergoing VD because of the smaller samples and the inadequate evidence from the included trials. In addition, the test of subgroup differences indicated the model of delivery had a potential effect on the efficacy of TA administration in reducing total and intraoperative blood loss.

TA, as an antifibrinolytic drug, has been routinely used in cardiac, orthopedics, and oral surgeries. Relevant studies have demonstrated TA administration could reduce perioperative blood loss. Recent evidences from high-quality RCTs indicated that TA usage resulted in a significant reduction of blood loss in CS or VD. Their study indicated that TA usage resulted in a significant reduction in total blood loss of 80.1 mL in CS and 71.5 mL in VD. Heesen et al identified 7 trials in which 6 reported the usage of TA in CS and one reported the usage of TA in VD. Their results showed TA usage rendered a reduced blood loss by a mean volume of 140.29 mL blood loss as compared to control group. However, their study did not take into account the influence of mode of delivery, which might introduce bias. Faraoni et al conducted a meta-analysis with 10 trials that evaluated the efficacy of TA administration in reducing blood loss for women undergoing CS or VD. They concluded that TA administration significantly reduced blood loss and lowered the occurrence rate of PPH regardless of the mode of delivery. To guard against the effect of bias from the mode of delivery, we identified all available data and assessed whether the mode of delivery had a potential effect on the efficacy of TA in reducing blood loss. In addition, this was the 1st study that had evaluated systematically the usage of TA in CS or VD according to 3 different time periods.

Our findings indicated TA administration reduced in total blood loss at a mean volume of 154.25 and 84.79 mL in CS and VD, respectively, and no increased risk of thromboembolic complications occurred. In addition, there was a higher heterogeneity existing, which may have caused several potential limitations. First, of the 25 studies, 23 trials measured the blood loss by visual estimation method and only 2 trials evaluated the blood loss using a mathematical calculation estimation method. Although the current standard practice of PPH assessment is visual estimation, it has been reported to be inaccurate by many authors because the method depends strongly on the operators’ subjective judgments. Second, all authors in the included trials have clearly mentioned that their methods did not take amniotic fluid quantity into account. However, it was difficult for avoiding blood loss mixed by amniotic fluid, which might overestimate the amount of blood loss. Finally, the limitation was the usage of oxytocin regimens and other uterotonic drugs. In a trial by Movafegh et al, patients received 30 units oxytocin during the first 8 hours postoperatively followed by 10 units of oxytocin in the case of uterine atony. Gohel Mayur at al described that patients received 10 units oxytocin followed by 0.4 mg methylergometrine, whereas
Ramani and Nayak\textsuperscript{[31]} applied the same dose of oxytocin infusion followed by 10 units as intramuscular along with 400 mg of tablet misoprostol sublingually after delivery of placenta. It is known that the oxytocin usage could reduce blood loss, which may overestimate the efficacy of TA. Although the use of TA resulted in a reduction of blood loss, statistically significant differences in blood loss might not always convey a parallel clinical significance because a mean blood loss of 150mL was

![Figure 3. Forest plot diagram showing the effect of tranexamic acid (TA) administration in cesarean section and vaginal delivery on total blood loss (A), intraoperative blood loss (B), and postoperative blood loss (C).](image-url)

| Study or Subgroup | Tranexamic acid | Control | Mean Difference (IV, Random, 95% CI) | Mean Difference (IV, Random, 95% CI) |
|-------------------|-----------------|---------|---------------------------------------|---------------------------------------|
| Cesarean section  |                 |         |                                       |                                       |
| Abd-el-Aal 2013   | 248.1 ± 126.02  | 731 ± 510.7 ± 144.52 ± 367 | 6.1% ± 299.09 ± 208.64 ± 294.59 |                                       |
| Ahmed 2014        | 184 ± 48.55     | 82 ± 597.6 ± 38.02 | 6.6% ± 205.79 ± 17.05 ± 36 |                                       |
| Ge 2004           | 109.2 ± 152.02  | 91 ± 493.6 ± 151.48 | 5.2% ± 80.07 ± 103.01 ± 29.49 |                                       |
| Gong 2011         | 499.9 ± 269.06  | 330 ± 600.7 ± 215.7 ± 330 | 10.6% ± 100.0 ± 135.01 ± 63.8 |                                       |
| Heter 2013        | 909 ± 90.91     | 50 ± 1044.0 ± 104.72 | 51.8% ± 14.0 ± 52.44 ± 4.44 |                                       |
| Meenal 2013       | 774 ± 74.64     | 100 ± 700.3 ± 189.1 | 100% ± 249.9 ± 278.2 ± 209.06 |                                       |
| More 2007         | 374.9 ± 51.48   | 50 ± 479.7 ± 43.54 | 50.6% ± 97.8 ± 116.35 ± 79.18 |                                       |
| Naseem 2014       | 260 ± 17.25     | 60 ± 481.1 ± 12.06 | 6.5% ± 221.0 ± 220.3 ± 21.05 |                                       |
| Pesana 2014       | 210 ± 17.59     | 60 ± 481.1 ± 12.06 | 6.5% ± 221.0 ± 220.3 ± 21.05 |                                       |
| Raama 2014        | 222 ± 97.02     | 60 ± 274.3 ± 179.2 | 60.0% ± 111.9 ± 101.07 ± 9.87 |                                       |
| Suresh 2013       | 373.7 ± 61.86   | 100 ± 389.8 ± 68.6 | 68.6% ± 124.0 ± 133.8 ± 12.05 |                                       |
| Surtani 2013      | 372.5 ± 143.23  | 101 ± 349.1 ± 89.49 | 52.3% ± 74.8 ± 118.35 ± 31.11 |                                       |
| Tse 2005          | 706.5 ± 38.00   | 100 ± 365.4 ± 38.16 | 38.1% ± 229.4 ± 364.88 ± 123.03 |                                       |
| Xu 2012           | 372 ± 106.12    | 60 ± 234.6 ± 183.3 | 51.5% ± 122.1 ± 104.1 ± 10.32 |                                       |
| Yeh 2014          | 454 ± 101.65    | 100 ± 735.4 ± 171 | 171.0% ± 126.9 ± 130.7 ± 26.7 |                                       |
| Total (95% CI)    |                |         |                                       |                                       |
| Mean Difference (IV, Random, 95% CI) |                |         |                                       |                                       |
| Mean Difference (IV, Random, 95% CI) |                |         |                                       |                                       |

**Figure 3.** Forest plot diagram showing the effect of tranexamic acid (TA) administration in cesarean section and vaginal delivery on total blood loss (A), intraoperative blood loss (B), and postoperative blood loss (C).
common in pregnancy women and most of women undergoing CS or VD were young and healthy. However, for patients with severe anemia or cardiovascular diseases, blood loss of as little as 200mL might be a life-threatening. In addition, it was unclear whether the reduction of the volume of blood loss was associated with other potential benefits of TA. Levy discussed the relation between the reduction of blood loss and the major favorable TA effect on mortality and morbidity in trauma patients and emphasized that the potential and unexplored side benefits of TA needed further research.150

Traditional, PPH has been defined as blood loss in excess of 500mL following a VD, or a loss of more than 1000mL following CS.199 Because the occurrence rate of PPH will be influenced by the total volume of blood loss and also the response to treatment, the Royal College of Obstetricians and Gynaecologists (RCOG) recommended that 500mL of blood loss is used as

![Forest plot diagram showing the effect of TA administration in cesarean section and vaginal delivery on the number of PPH (A), severe PPH (B), and transfusion needs (C). PPH = postpartum hemorrhage, TA = tranexamic acid.](image-url)
a point of “alert,” while treatment is only performed once the patient loses over 1000mL of blood.[51] The effect of TA on PPH is important, especially for CS, as maternal deaths usually occur when blood loss is over 1000mL.[51] Our findings indicated that TA usage rendered a significant reduction of PPH and severe PPH in both CS and VD. However, the current level of evidence was insufficient to reach a definitive conclusion. The rate of PPH varied greatly depending on the criteria that were used to define it, and it was not the same among different regions around the world, which might be associated with a higher heterogeneity.

The rate of thromboembolic events during pregnancy and puerperium is higher than that in the general population.[1] Thus,
the safety of TA administration for pregnancy women must be evaluated carefully. Previous studies evaluating the usage of TA in oral, cardiac, and orthopedic surgeries, and recent studies evaluating the usage of TA in obstetrics have confirmed its safety. A study by Heesen et al evaluated the usage of TA in 1578 participants who undergoing CS or VD and showed no associated between TA usage and the incidence of thromboembolic events. Our findings showed 4 thromboembolic events in CS following TA administration, which had no significant difference with control group. However, caution was required in the interpretation of these results due to the lower rate of complication and the different methods of DVT screening. Thus, a prolonged treatment with TA should be monitored closely to avoid the risk for underlying thrombosis. Our study was not powered to address safety issues, because the minor side effects including gastrointestinal and neurological manifestations, which were mild and reversible, were higher in TA administration than control group. Although the minor side effects were not the same importance with thromboembolic events, it was essential to balance the clinical effect of TA in reducing blood loss with disabling symptoms. Whether a lower dosage of TA rendered a lower risk of complications needed further studies. In addition, studies evaluating the effective of TA on neonate reported no difference regarding neonatal Apagar score in both groups and no other adverse neonatal outcomes occurred after prophylactic TA administration. Thus, the usage of TA is safety for neonate.

4.1. Strength

The reliability and robustness of the pooled results were supported by the most rigorous assessment of methodology quality of included studies in our meta-analysis: the comprehensive literature search without language restrictions and including the gray literature and conference proceedings; a relative large number of studies in the systematic review, most of which were published in recent years; the quantitative summary of the evidence; the performance of subgroup analyses according to the mode of delivery; the analysis of blood loss according to the different time period; and the sensitivity analysis restricted to trials with low risk of bias.

5. Limitation

Some limitations of this study should be acknowledged. There was substantial statistical heterogeneity existing for several outcomes, especially for bleeding volume. Therefore, our findings should be interpreted in this context. To reduce the clinical heterogeneity among the included studies, we used random effects models to pool data across studies to attempt to incorporate any heterogeneity and explore possible sources of heterogeneity. In addition, the mean difference for evaluating the amount of reduced blood loss was adopted between TA and control group. Despite this, we could not explain most of the heterogeneity, which might be due to the differences in study population, doses of TA or usage of addition uterine drugs, cesarean delivery technique, surgical experience, method of assessment of blood loss, or study implementation. Only 3 studies with small samples were included to evaluate the usage of TA in VD, which might result in a certain bias of the conclusion. In addition, because unpublished data could not be required, we could not fully exclude the publication bias. The majority of studies included relatively small sample size, which perhaps affected the accuracy of the conclusion. Although some studies stated that TA was a cheap drug and did not increase the cost of patients, no study presented the detailed data in their results. Thus, the data were inadequate to pool and the conclusion of cost was unconvincing. Finally, similar with any meta-analyses, ours was limited by the quality of original data.

6. Conclusion

Based on the current evidence, the present meta-analysis demonstrates that TA administration in CS significantly could reduce blood loss, lower the incidence rate of PPH, and severe PPH, and render a significant reduction in blood needs without no apparent increase in harm. Thus, TA seems to be an efficacious and safe drug in patients undergoing CS. However, data are insufficient to evaluate the clinical effect of TA in patients undergoing VD because of the smaller samples and the lower methodology quality of included studies. Therefore, further well-designed RCTs with larger samples are needed to validate our findings.

References

[1] AbouZahr C. Global burden of maternal death and disability. Br Med Bull 2003;67:1-1.
[2] IKambo I, Redi N, Dhillon BS, et al. A critical appraisal of cesarean section rates at teaching hospitals in India. Int J Gynecol Obstet 2002;79:151-8.
[3] Pau LM. Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis. Drugs 2012;72:585-617.
[4] Wang C, Xu GJ, Han Z, et al. Topical application of tranexamic acid in primary total hip arthroplasty: a systemic review and meta-analysis. Int J Surg 2015;13:134-9.
[5] Cherityan T, Mauer SP 2nd, Bianco K, et al. Efficacy of tranexamic acid on surgical bleeding in spine surgery: a meta-analysis. Spine J 2015;15:752-61.
[6] Farazomi D, Willems A, Melot C, et al. Efficacy of tranexamic acid in paediatric cardiac surgery: a systematic review and meta-analysis. Eur J Cardiothorac Surg 2012;42:781-6.
[7] Naoulou B, Tsai MC. Efficacy of tranexamic acid in the treatment of idiopathic and non-functional heavy menstrual bleeding: a systematic review. Acta Obstet Gynecol Scand 2012;91:529-37.
[8] Topoe MF, Bergholt T, Ravn P, et al. Anti-hemorrhagic effect of prophylactic tranexamic acid in benign hysterectomy—a double-blinded randomized placebo-controlled trial. Acta Ostet Gynecol Scand 2016;215:72. e1-8.
[9] Shaaban MM, Ahmed MR, Farhan RE, et al. Efficacy of tranexamic acid on myomectomy-associated blood loss in patients with multiple myomas: a randomized controlled clinical trial. Reprod Sci 2016;23:908–12.
[10] Gai MY, Wu LF, Su QF, et al. Clinical observation of blood loss reduced by tranexamic acid during and after cesarean section: a multi-center, randomized trial. Euro J Obstet, Gynecol, Reprod Biol 2004;122:154–7.
[11] Gohel Mayur PP, Gupta A, Desai P. Efficacy of tranexamic acid in decreasing blood loss during and after cesarean section: A randomized case controlled prospective study. J Obstet Gynecol India 2007;57:227–30.
[12] Sekhavat L, Tabatabaii A, Dalili M, et al. Efficacy of tranexamic acid in reducing blood loss after cesarean section. Int J Gynaecol Obstet 2009;102:72–5.
[13] Rashmi PS, Sudha TR, Prema P, et al. Roll of Tranexamic acid in reducing blood loss during and after cesarean section a randomized case control prospective study. J Med Res Pract 2010;1:40–3.
[14] Gungorduk K, Yildirim G, Asicioglu O, et al. Efficacy of intravenous tranexamic acid in reducing blood loss after elective cesarean section: a prospective, randomized, double-blind, placebo-controlled study. Am J Perinatol 2011;28:233–40.
[15] Movafegh A, Eslamian L, Dorabadi A. Effect of intravenous tranexamic acid administration on blood loss during and after cesarean delivery. Int J Gynaecol Obstet 2011;115:224–6.
[16] Poonia M, Bhardwaj N, Bhardwaj N, et al. Role of Tranexamic acid in reducing blood loss after caesarean section: a randomized case control prospective study. J Med Sci Res 2012;3:44–5.
[17] Abdel-Aleem H, Alhusaini TK, Abdel-Aleem MA, et al. Effectiveness of tranexamic acid on blood loss in patients undergoing elective caesarean section: randomized clinical trial. J Matern Fetal Neonatal Med 2013;26:1705–9.
[18] Shahid A, Khan K. Tranexamic acid in decreasing blood loss during and after caesarean section. J Coll Physicians Surg Pak 2013;23:459–62.
[19] Goswami U, Sarangi S, Gupta S, et al. Comparative evaluation of two doses of tranexamic acid used prophylactically in anemic parturients for lower segment cesarean section: A double-blind randomized case control prospective trial. Saudi J Anaesth 2013;7:427–31.
[20] Halder S, Samanta B, Sardar R, et al. Tranexamic acid used before caesarean section reduces blood loss based on pre- and postoperative haemoglobin level: a case-control study. J India Med Assoc 2013;111:184–6.
[21] Senturk MB, Cakmak Y, Yildiz G, et al. Tranexamic acid for cesarean section: a double-blind, placebo-controlled, randomized clinical trial. Arch Gynecol Obstet 2013;287:641–5.
[22] Xu J, Gao W, Ju Y. Tranexamic acid for the prevention of postpartum hemorrhage after caesarean section: a double-blind randomization trial. Arch Gynecol Obstet 2013;287:463–8.
[23] Ahmed MR, Sayed Ahmed WA, Madny EH, et al. Efficacy of tranexamic acid in decreasing blood loss in elective caesarean delivery. J Matern Fetal Neonatal Med 2014;5:287.
[24] Ghosh A, Chaudhuri P, Muhuri B. Efficacy of intravenous tranexamic acid before cesarean section in preventing post partum hemorrhage-a prospective randomized double blind placebo controlled study. Int J Bio Med Res 2015;4:4461–4.
[25] Gobbur V, Shiragur S, Jhanwar U, et al. Efficacy of tranexamic acid in reducing blood loss during lower segment caesarean section. Int J Reprod Contracept Obstet Gynecol 2014;3:414.
[26] Taj N, Firdous A, Akhtar N, et al. Efficacy of tranexamic acid in reducing blood loss during and after cesarean section. Ra Med J 2014;10:391–3.
[27] Singh T, Burute SB, Deshpande HG, et al. Efficacy of tranexamic acid in decreasing blood loss during and after cesarean section: a randomized case control prospective study. J Evol Med Dent Sci 2014;3:2780–8.
[28] Yehia AH, Koleih MH, Abdelazim IA, et al. Tranexamic acid reduces blood loss during and after cesarean section: A double blinded, randomized, controlled trial. Asian Pac J Reprod 2014;3:53–6.
[29] Maged AM, Helal OM, Elsherbini MM, et al. A randomized placebo-controlled trial of preoperative tranexamic acid among women undergoing elective cesarean delivery. Int J Gynaecol Obstet 2015;131:263–8.
[30] Sujata N, Tobin R, Kaur R, et al. Randomized controlled trial of tranexamic acid among parturients at increased risk for postpartum hemorrhage undergoing caesarean delivery. Int J Gynaecol Obstet 2016;133:312–5.
[31] Ramani B, Nayak L. Intravenous 1 gram tranexamic acid for prevention of blood loss and blood transfusion during cesarean section: a randomized case control study. Int J Reprod Contracept Obstet Gynecol 2014;3:366.
[32] Yang H, Zhang S, Shi C, et al. Clinical study on the efficacy of tranexamic acid in reducing postpartum blood lose: a randomized, comparative, multicenter trial. Zhonghua Fu Chan Ke Za Zhi 2001;36:590–2.
[33] Gungorduk K, Ascioglu O, Yildirim G, et al. Can intravenous injection of tranexamic acid be used in routine practice with active management of the third stage of labor in vaginal delivery? A randomized controlled study. Am J Perinatol 2013;30:407–13.
[34] MirdhaSourav M, Mohammad-Alizadeh S, Abbasalizadeh F, et al. The effect of prophylactic intravenous tranexamic acid on blood loss after vaginal delivery in women at low risk of postpartum haemorrhage: a double-blind randomised controlled trial. Aust N Z J Obstet Gynaecol 2013;53:53–8.
[35] Park JH, Park CR. Antifibrinolytic therapy with tranexamic acid in pregnancy and postpartum. Expert Opin Pharmacother 2011;12:503–16.
[36] Ferrer P, Roberts I, Sydenham E, et al. Anti-fibrinolytic agents in post partum haemorrhage: a systematic review. BMC Pregnancy Childbirth 2009;9:29.
[37] Hessen M, Bohmer J, Kloho S, et al. Prophylactic tranexamic acid in parturients at low risk for post-partum haemorrhage: systematic review and meta-analysis. Acta Anaesthesiol Scand 2014;58:1075–85.
[38] Novikova N, Hofmeyr G. Tranexamic acid for preventing postpartum haemorrhage. Cochrane Database Syst Rev 2010;7:CD007872.
[39] Chi BH. Translating clinical management into an effective public health response for postpartum haemorrhage. BJOG 2015;122:211.
[40] Nadisauskienė RJ, Kluočius A, Dobrosiūnienė M, et al. The impact of postpartum haemorrhage management guidelines implemented in clinical practice: a systematic review of the literature. Eur J Obstet Gynecol Reprod Biol 2014;178:21–6.
[41] Sharma R, Najam R, Misra MK. Efficacy of tranexamic acid in decreasing blood loss during and after cesarean section. Biomed Pharmacol J 2011;4:231–5.
[42] Sahaf F, Abbasalizadeh S, Ghofzadeh M, et al. Comparison effect of intravenous tranexamic acid and misoprostol for postpartum haemorrhage. Nig Med J 2015;55:348–53.
[43] Shukur H, Gilmezoglu M, Alrefiev Z, et al. The WOMAN Trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trial. Trials 2010;11:40.
[44] Ducloy-Bouthors AS, Jude B, Duhamel A, et al. High-dose tranexamic acid reduces blood loss in postpartum haemorrhage. Crit Care 2011;15:R117.
[45] Vigna-Taglianti F, Basso L, Rolfo P, et al. Tranexamic acid for reducing blood transfusions in arthroplasty interventions: a cost-effective practice. Eur J Orthop Surg Traumatol 2014;24:545–51.
[46] Sepah YJ, Umer M, Ahmad T, et al. Use of tranexamic acid is a cost effective method in preventing blood loss during and after total knee replacement. J Orthop Surg Res 2011;6:22.
[47] Faraoni D, Carlier C, Samama CM, et al. Efficacy and safety of tranexamic acid administration for the prevention and/or the treatment of post-partum haemorrhage: a systematic review with meta-analysis. Ann Fr Anesth Reanim 2014;33:563–71.
[48] Gabel KT, Weber TA. Measuring and communicating blood loss during obstetric hemorrhage. J Obstet Gynecol Neonatal Nurs 2012;41:551–8.
[49] Patel A, Goudar SS, Geller SE, et al. Drape estimation vs. visual assessment for estimating postpartum hemorrhage. Int J Gynaecol Obstet 2006;93:220–4.
[50] Levy JH. Antithrombotic therapy: new data and new concepts. Lancet 2006;368:943–9.
[51] Dahlke JD, Mendez-Figueroa H, Maggio L, et al. Prevention and management of postpartum hemorrhage: a comparison of 4 national guidelines. AJOG 2013;213:76.e1–0.